Key points from article :
GenSight using gene therapy and a wearable device to restore sight in patients with retinitis pigmentosa.
Medicines and Healthcare Regulatory Agency has accepted application to run a clinical trial in the UK.
Gene therapy encodes for a protein sensitive to light into specific neurons.
Goggles capture images and transform them into light patterns that stimulate the proteins.
GS030 phase I/II trial should measure the outcome in early 2019.
Retinitis pigmentosa is a genetic disease that leads to blindness by age 40.
Therapy could be extended to other retinal diseases such as dry-AMD.
